ESMO 2022 | TUXEDO-1: QoL and neurocognitive function in HER2-positive BC w/ brain metastasis treated with T-DXd

Angelika Starzer, MD, Medical University of Vienna, Vienna, Austria, provides an overview of quality of life and neurocognitive function in patients with active brain metastases of HER2-positive breast cancer treated with trastuzumab deruxtecan in patients enrolled in the Phase II TUXEDO-1 trial (NCT04752059). Quality of life and neurocognitive function were maintained in the TUXEDO-1 trial which supports first-line systemic therapy with trastuzumab deruxtecan in patients with active brain metastases. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.